A statement from the APA’s Telepsychiatry and Mental Health IT Committees on Patient Safety and Quality
Last month, the U.S. House of Representatives passed H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act. The bill now goes to the U.S. Senate for consideration and deliberation of what measures will be included in a possible mental health legislative package.
The social determinants of health and mental health were the focus of a recent APA Mental Health Equity Fireside Chat hosted by APA’s Division of Diversity and Health Equity and moderated by Division Chief and Deputy Medical Director Regina James, M.D.
- By Saul Levin, M.D., M.P.A., FRCP-E, FRCPsych
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to monitor prescribing and dispensing of the drug, which is used to treat schizophrenia. The new REMS led to confusion for manufacturers, pharmacies, prescribers, and patients. Some clinicians stopped prescribing the already underutilized drug, and some pharmacies stopped dispensing it. This chaotic situation led the FDA to stop enforcing certain requirements of the REM for 90 days.
March is Women’s History Month and we’re highlighting several women currently leading the organization: APA President Vivian Pender, M.D., President-Elect Rebecca W. Brendel, M.D., J.D., and Assembly Speaker Mary Jo Fitz-Gerald, M.D., M.B.A.